Loading...
XHKG
2192
Market cap1.40bUSD
Jul 18, Last price  
15.02HKD
1D
0.13%
1Q
30.61%
IPO
-50.02%
Name

Medlive Technology Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
31.95
P/S
18.03
EPS
0.43
Div Yield, %
1.79%
Shrs. gr., 5y
1.30%
Rev. gr., 5y
35.65%
Revenues
558m
+35.55%
83,463,000121,569,000213,529,000284,440,000314,054,000412,004,000558,455,000
Net income
315m
+30.06%
14,189,00031,270,00085,197,00040,616,000117,321,000242,301,000315,146,000
CFO
0k
-100.00%
22,091,00028,203,000111,048,00044,433,00077,189,000101,866,0000
Dividend
Oct 22, 20240.132 HKD/sh

Profile

Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, which includes project management, clinical monitoring, clinical data management, biostatistics, protocol design, medical monitoring, patient recruitment, and supporting system, as well as digital market research, electronic data capture, real-world studies, and application software development services. The company's medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. Its intelligent patient management solution provides chronic disease management services, comprising online patient consultation, prescription services, and patient management through Internet hospital; and condition-specific patient education services, which includes content development, application software development, and other related services. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. Medlive Technology Co., Ltd. was founded in 1996 and is headquartered in Beijing, China.
IPO date
Jul 15, 2021
Employees
668
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
558,455
35.55%
412,004
31.19%
314,054
10.41%
Cost of revenue
504,808
337,928
298,886
Unusual Expense (Income)
NOPBT
53,647
74,076
15,168
NOPBT Margin
9.61%
17.98%
4.83%
Operating Taxes
10,173
1,372
8,616
Tax Rate
18.96%
1.85%
56.80%
NOPAT
43,474
72,704
6,552
Net income
315,146
30.06%
242,301
106.53%
117,321
188.85%
Dividends
(124,687)
(12,133)
Dividend yield
2.02%
0.19%
Proceeds from repurchase of equity
5,261
5,014
BB yield
-0.09%
-0.08%
Debt
Debt current
11,601
4,549
5,136
Long-term debt
33,665
11,835
17,388
Deferred revenue
Other long-term liabilities
35,423
55,199
27,803
Net debt
(4,541,425)
(4,426,885)
(4,257,533)
Cash flow
Cash from operating activities
101,866
77,189
CAPEX
(750)
(7,488)
Cash from investing activities
(634,945)
(3,585,555)
Cash from financing activities
(133,130)
(22,380)
FCF
13,660
96,210
(3,336)
Balance
Cash
4,145,957
4,400,895
4,216,904
Long term investments
440,734
42,374
63,153
Excess cash
4,558,768
4,422,669
4,264,354
Stockholders' equity
4,854,618
741,546
514,344
Invested Capital
353,906
3,967,047
3,921,425
ROIC
2.01%
1.84%
0.17%
ROCE
1.09%
1.57%
0.34%
EV
Common stock shares outstanding
736,260
734,583
736,502
Price
9.92
17.81%
8.42
-1.29%
8.53
-68.64%
Market cap
7,303,696
18.08%
6,185,189
-1.55%
6,282,360
-63.67%
EV
2,817,862
1,806,137
2,055,718
EBITDA
53,647
83,447
24,155
EV/EBITDA
52.53
21.64
85.11
Interest
361
531
Interest/NOPBT
0.49%
3.50%